Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research report released on Wednesday morning.

A number of other research firms also recently weighed in on OMER. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Thursday, November 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, Rodman & Renshaw began coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price on the stock. Three research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Omeros Stock Performance

OMER stock opened at $10.91 on Wednesday. The firm has a market cap of $632.23 million, a PE ratio of -4.72 and a beta of 1.47. The firm has a fifty day moving average price of $4.50 and a 200 day moving average price of $4.23. Omeros has a fifty-two week low of $1.81 and a fifty-two week high of $10.99.

Hedge Funds Weigh In On Omeros

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in shares of Omeros by 75.5% during the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 12,951 shares during the period. Comerica Bank increased its stake in Omeros by 20.0% in the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 5,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after purchasing an additional 81,348 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares during the period. Finally, AQR Capital Management LLC bought a new position in shares of Omeros in the second quarter worth about $105,000. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.